Turner Syndrome Treatment & Management
- Author: Maala S Daniel, MBBS; Chief Editor: Luis O Rohena, MD more...
Turner syndrome is a lifelong condition. Most people live long and healthy lives, yet some are susceptible to numerous chronic conditions. Health supervision involves careful medical follow-up care, which includes screening for commonly associated chronic diseases. Early preventive care and treatment are also essential.
In childhood, growth hormone therapy is standard to prevent short stature as an adult.[14, 15, 16] The results of a double-blind, placebo-controlled trial show that the combination of growth hormone and ultra-low-dose estrogen in childhood may improve growth in patients with Turner syndrome. The ideal age for initiating treatment has not been established. Taller adult heights occur with the longest treatment durations before the start of puberty.
Estrogen replacement therapy is usually required, but starting too early or using doses that are too high can compromise adult height. Estrogen is usually started at age 12-15 years. Treatment can be started with continuous low-dose estrogens at 12 years, or as early as 5 years . These can be cycled in a 3-weeks on, 1-week off regimen after 6-18 months; progestin can be added later. Some authors believe that conjugated estrogens are contraindicated in pediatric patients. Transdermal estrogens are associated with physiologic estrogen levels , and may be preferred treatment, if tolerated.
Growth hormone may have long-term favorable effects on lipids, even after it is discontinued.
Patients are suspected of having a high risk of keloid formation. This must be taken into consideration if cosmetic surgery is contemplated because keloids may negate any gain from such procedures.
Subacute bacterial endocarditis (SBE) prophylaxis may be required prior to any dental or surgical procedure in women with cardiac valve disease to prevent SBE.
During childhood and adolescence, patients should visit a pediatric endocrinologist at regular intervals.
Attention should be paid to growth and development, thyroid status, and osteoporosis prevention with growth hormone, estrogens, and progestins.
Patients on growth hormone should be seen every 3-6 months.
A cardiologist should evaluate all patients at diagnosis.
Patients with systemic hypertension or aortic valve anomalies are at higher risk for aortic dissection.
Patients found to have significant anomalies should have long-term follow-up care and possibly SBE prophylaxis.
Because of the risks of aortic root dilatation and mortality due to aortic dissection, cardiac evaluation (including echocardiography) may be worthwhile every 5 years, even in patients with normal findings on initial cardiovascular examination.
Patients contemplating pregnancy should have a complete cardiovascular evaluation prior to attempting assisted reproduction or conception.
Patients with a bicuspid aortic valve, coarctation of the aorta, or dilation of the aorta have a higher risk of dissecting aortic aneurysm or rupture.
Nephrologist or urologist
Almost a third of patients have renal anomalies that may require evaluation and follow-up care by a nephrologist. At a minimum, such patients should have a yearly urine culture and an annual measurement of BUN and creatinine levels.
Girls with horseshoe kidneys have an increased risk of Wilms tumor. Patients with horseshoe kidneys should have renal ultrasound examinations every 4-6 months until the age 8 years and every 6-12 months thereafter.
Overall psychological health is good, but specific perceptual weaknesses or learning disabilities may be present. Assessment of intelligence, learning ability, motor skills, and social maturity should be made prior to enrollment in kindergarten. 
Problems with math and with visual spatial skills (eg, map reading) are common.
Attention deficit hyperactivity disorder is more common in girls with Turner syndrome than in girls in general.
Intelligence is usually normal, but individuals with ring chromosomes may have impaired intelligence.
As with any chronic illness, attention should be paid to fostering healthy socialization and to appropriate career and vocational planning. Patients with Turner syndrome are more likely to be employed than other adult women, although less likely to be married. 
Turner syndrome is not an inherited disorder, and the recurrence risk is low.
Because of infertility, the syndrome is rarely passed to offspring.
Consultation is helpful when the condition is diagnosed in utero or when Turner syndrome is suspected in the setting of a normal peripheral blood karyotype.
Patients should be tested for the presence of Y-chromosomal material using a Y-centromeric probe.
Dietary requirements are similar to those of other children or adults.
Both short stature and ovarian failure are risk factors for osteoporosis, and care should be taken to ensure adequate daily intake of calcium (1.0-1.5 g) and vitamin D (at least 400 IU).
Patients should avoid obesity because it increases already high risks of hypertension and insulin resistance.
Patients with short stature require fewer calories than those of normal height.
Turner HH. A syndrome of infantilism, congenital webbed neck, and cubitus valgus. Endocrinology. 1938. 23:566-574.
[Guideline] Donaldson MD, Gault EJ, Tan KW, Dunger DB. Optimising management in Turner syndrome: from infancy to adult transfer. Arch Dis Child. 2006 Jun. 91(6):513-20. [Medline].
Lyon AJ, Preece MA, Grant DB. Growth curve for girls with Turner syndrome. Arch Dis Child. 1985 Oct. 60(10):932-5. [Medline].
Sculerati N, Ledesma-Medina J, Finegold DN, Stool SE. Otitis media and hearing loss in Turner syndrome. Arch Otolaryngol Head Neck Surg. 1990 Jun. 116(6):704-7. [Medline].
Natowicz M, Kelley RI. Association of Turner syndrome with hypoplastic left-heart syndrome. Am J Dis Child. 1987 Feb. 141(2):218-20. [Medline].
Pai GS, Leach DC, Weiss L, Wolf C, Van Dyke DL. Thyroid abnormalities in 20 children with Turner syndrome. J Pediatr. 1977 Aug. 91(2):267-9. [Medline].
Alpman A, Cogulu O, Akgul M, et al. Prenatally Diagnosed Turner Syndrome and Cystic Hygroma: Incidence and Reasons for Referrals. Fetal Diagn Ther. 2008 Mar 12. 25(1):58-61. [Medline].
Carr RF, Ochs RH, Ritter DA, Kenny JD, Fridey JL, Ming PM. Fetal cystic hygroma and Turner's syndrome. Am J Dis Child. 1986 Jun. 140(6):580-3. [Medline].
Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2015 Mar. 45 (3):249-66. [Medline].
[Guideline] Davenport ML. Approach to the patient with Turner syndrome. J Clin Endocrinol Metab. 2010 Apr. 95(4):1487-95. [Medline].
[Guideline] Bondy CA. Care of girls and women with Turner syndrome: A guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 2007 Jan. 92(1):10-25. [Medline].
Conte FA, Grumbach MM, Kaplan SL. A diphasic pattern of gonadotropin secretion in patients with the syndrome of gonadal dysgenesis. J Clin Endocrinol Metab. 1975 Apr. 40(4):670-4. [Medline].
Elsheikh M, Conway GS, Wass JA. Medical problems in adult women with Turner's syndrome. Ann Med. 1999 Apr. 31(2):99-105. [Medline].
Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, Fechner PY, et al. Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial. J Clin Endocrinol Metab. 2007 Sep. 92(9):3406-16. [Medline].
Backeljauw P. Does growth hormone therapy before 4 years of age enhance the linear growth of girls with Turner's syndrome?. Nat Clin Pract Endocrinol Metab. 2008 Feb. 4(2):78-9. [Medline].
Bolar K, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in turner syndrome. J Clin Endocrinol Metab. 2008 Feb. 93(2):344-51. [Medline].
Bannink EM, van der Palen RL, Mulder PG, de Muinck Keizer-Schrama SM. Long-term follow-up of GH-treated girls with Turner syndrome: metabolic consequences. Horm Res. 2009. 71(6):343-9. [Medline].
Ankarberg-Lindgren C, Elfving M, Wikland KA, Norjavaara E. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. J Clin Endocrinol Metab. 2001 Jul. 86(7):3039-44. [Medline].
Zuckerman-Levin N, Frolova-Bishara T, Militianu D, Levin M, Aharon-Peretz J, Hochberg Z. Androgen replacement therapy in Turner syndrome: a pilot study. J Clin Endocrinol Metab. 2009 Dec. 94(12):4820-7. [Medline].
Morgan T. Turner syndrome: diagnosis and management. Am Fam Physician. 2007 Aug 1. 76 (3):405-10. [Medline].
Donadille B, Rousseau A, Zenaty D, Cabrol S, Courtillot C, Samara-Boustani D, et al. CARDIOVASCULAR FINDINGS AND MANAGEMENT IN TURNER SYNDROME: INSIGHTS FROM A FRENCH COHORT. Eur J Endocrinol. 2012 Jul 16. [Medline].
Jorgensen KT, Rostgaard K, Bache I, et al. Autoimmune diseases in women with Turner's syndrome. Arthritis Rheum. 2010 Mar. 62(3):658-66. [Medline].
Heinrichs C, Bourdoux P, Saussez C, Vis HL, Bourguignon JP. Blood spot follicle-stimulating hormone during early postnatal life in normal girls and Turner's syndrome. J Clin Endocrinol Metab. 1994 Apr. 78(4):978-81. [Medline].
Ross JL, Quigley CA, Cao D, Feuillan P, Kowal K, Chipman JJ. Growth hormone plus childhood low-dose estrogen in Turner's syndrome. N Engl J Med. 2011 Mar 31. 364(13):1230-42. [Medline].
Illig R, Tolksdorf M, Mürset G, Prader A. LH and FSH response to synthetic LH-RH in children and adolescents with Turner's and Klinefelter's syndrome. Helv Paediatr Acta. 1975 Oct. 30(3):221-31. [Medline].
Samarakoon L, Sirisena ND, Wettasinghe KT, Kariyawasam KW, Jayasekara RW, Dissanayake VH. Prevalence of chromosomal abnormalities in Sri Lankan women with primary amenorrhea. J Obstet Gynaecol Res. 2012 Dec 21. [Medline].
[Guideline] Frias JL, Davenport ML. Health supervision for children with Turner syndrome. Pediatrics. 2003 Mar. 111(3):692-702. [Medline].
Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet. 1997 May. 16(1):54-63. [Medline].
Bianco B, Lipay MV, Melaragno MI, Guedes AD, Verreschi IT. Detection of hidden Y mosaicism in Turner's syndrome: importance in the prevention of gonadoblastoma. J Pediatr Endocrinol Metab. 2006 Sep. 19(9):1113-7. [Medline].
Birdsall M, Kennedy S. The risk of aortic dissection in women with Turner syndrome. Hum Reprod. 1996 Jul. 11(7):1587. [Medline].
Nadeem M, Roche EF. Bone health in children and adolescent with Turner syndrome. J Pediatr Endocrinol Metab. 2012. 25(9-10):823-33. [Medline].
Ross JL, Quigley CA, Cao D, Feuillan P, Kowal K, Chipman JJ, et al. Growth hormone plus childhood low-dose estrogen in Turner's syndrome. N Engl J Med. 2011 Mar 31. 364(13):1230-42. [Medline].
Hong DS, Dunkin B, Reiss AL. Psychosocial functioning and social cognitive processing in girls with turner syndrome. J Dev Behav Pediatr. 2011 Sep. 32(7):512-20. [Medline].
Gould HN, Bakalov VK, Tankersley C, Bondy CA. High levels of education and employment among women with turner syndrome. J Womens Health (Larchmt). 2013 Mar. 22(3):230-5. [Medline].
Stephure DK. Impact of growth hormone supplementation on adult height in turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab. 2005 Jun. 90(6):3360-6. [Medline].
Bender B, Puck M, Salbenblatt J, Robinson A. Cognitive development of unselected girls with complete and partial X monosomy. Pediatrics. 1984 Feb. 73(2):175-82. [Medline].
Price WH, Clayton JF, Collyer S, De Mey R, Wilson J. Mortality ratios, life expectancy, and causes of death in patients with Turner's syndrome. J Epidemiol Community Health. 1986 Jun. 40(2):97-102. [Medline].
Garden AS, Diver MJ, Fraser WD. Undiagnosed morbidity in adult women with Turner's syndrome. Clin Endocrinol (Oxf). 1996 Nov. 45(5):589-93. [Medline].
Hovatta O. Pregnancies in women with Turner's syndrome. Ann Med. 1999 Apr. 31(2):106-10. [Medline].
Kaneko N, Kawagoe S, Hiroi M. Turner's syndrome--review of the literature with reference to a successful pregnancy outcome. Gynecol Obstet Invest. 1990. 29(2):81-7. [Medline].
Wasserman D, Asch A. Reproductive medicine and Turner syndrome: ethical issues. Fertil Steril. 2012 Oct. 98(4):792-6. [Medline].
Chorazy PA, Himelhoch S, Hopwood NJ, Greger NG, Postellon DC. Persistent hypothyroidism in an infant receiving a soy formula: case report and review of the literature. Pediatrics. 1995 Jul. 96(1 Pt 1):148-50. [Medline].
Davenport ML, Punyasavatsut N, Stewart PW, Gunther DF, Savendahl L, Sybert VP. Growth failure in early life: an important manifestation of Turner syndrome. Horm Res. 2002. 57(5-6):157-64. [Medline].
Even L, Cohen A, Marbach N, Brand M, Kauli R, Sippell W, et al. Longitudinal analysis of growth over the first 3 years of life in Turner's syndrome. J Pediatr. 2000 Oct. 137(4):460-4. [Medline].
Fryer SL, Kwon H, Eliez S, Reiss AL. Corpus callosum and posterior fossa development in monozygotic females: a morphometric MRI study of Turner syndrome. Dev Med Child Neurol. 2003 May. 45(5):320-4. [Medline].
Goldacre MJ, Seminog OO. Turner syndrome and autoimmune diseases: record-linkage study. Arch Dis Child. 2013 Sep 24. [Medline].
[Guideline] Gravholt C. Clinical Practice in Turner Syndrome. Nature Clinical Practice Endocrinology & Metabolism. 2005. 1:41-52.
Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol. 1998 Feb. 51(2):147-58. [Medline].
Hasle H, Olsen JH, Nielsen J, Hansen J, Friedrich U, Tommerup N. Occurrence of cancer in women with Turner syndrome. Br J Cancer. 1996 May. 73(9):1156-9. [Medline].
Health supervision for children with Turner syndrome. American Academy of Pediatrics. Committee on Genetics. Pediatrics. 1995 Dec. 96(6):1166-73. [Medline].
Lippe BM. Primary Ovarian Failure. Clinical Pediatric Endocrinology. Philadelphia, Pa: WB Saunders; 1990: 325-366.
Mazzanti L, Prandstraller D, Tassinari D, Rubino I, Santucci S, Picchio FM, et al. Heart disease in Turner's syndrome. Helv Paediatr Acta. 1988 Aug. 43(1-2):25-31. [Medline].
Medeiros CC, Marini SH, Baptista MT, Guerra G Jr, Maciel-Guerra AT. Turner's syndrome and thyroid disease: a transverse study of pediatric patients in Brazil. J Pediatr Endocrinol Metab. 2000 Apr. 13(4):357-62. [Medline].
Miller G. Study Charts Constellation of Turner Syndrome-Related Autoimmune Diseases. Available at http://www.medscape.com/viewarticle/812298. Accessed: October 21, 2013.
Neumann PJ, Gharib SD, Weinstein MC. The cost of a successful delivery with in vitro fertilization. N Engl J Med. 1994 Jul 28. 331(4):239-43. [Medline].
Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, van Teunenbroek A, Hokken-Koelega AC, Waelkens JJ, et al. Final height in girls with Turner's syndrome treated with once or twice daily growth hormone injections. Dutch Advisory Group on Growth Hormone. Arch Dis Child. 1999 Jan. 80(1):36-41. [Medline]. [Full Text].
Soriano-Guillen L, Coste J, Ecosse E, et al. Adult height and pubertal growth in Turner syndrome after treatment with recombinant growth hormone. J Clin Endocrinol Metab. 2005 Sep. 90(9):5197-204. [Medline]. [Full Text].
Starke M, Albertsson Wikland K, Möller A. Parents' descriptions of development and problems associated with infants with Turner syndrome: a retrospective study. J Paediatr Child Health. 2003 May-Jun. 39(4):293-8. [Medline].
Zinn AR, Ross JL. Molecular analysis of genes on Xp controlling Turner syndrome and premature ovarian failure (POF). Semin Reprod Med. 2001 Jun. 19(2):141-6. [Medline].